---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-207867"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:32:13.115066+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash

## Summary
- Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).
- Name changed from Cortexyme to Quince Therapeutics; ticker changes from CRTX to QNCX effective Aug 1, 2022.
- Strategic focus on bone-targeting drug platform and lead molecule NOV004; Phase 1 clinical studies expected in 2023.
- Plans to in-license or acquire clinical-stage assets for debilitating/rare diseases and out-license legacy neuroscience assets.
- Cash runway expected to fund operations into second half of 2025; corporate restructuring completed in H1 2022.

## SEC filing metadata
- accession: 0001193125-22-207867
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/0001193125-22-207867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/d346512d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-207867
- JSON: https://secwatch.observer/filing/0001193125-22-207867.json
- Plain text: https://secwatch.observer/filing/0001193125-22-207867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.